Cooley LLP announced today that it represented AcelRx Pharmaceuticals, Inc. in its public offering of approximately 4.8 million shares of common stock. AcelRx is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain.
The offering closed on July 23, 2013.
The chair of Cooley’s medical device practice, Mark Weeks, led the offering, and he teamed with partner Chadwick Mills and special counsel Marina Remennik on corporate securities matters. Partners Natasha Leskovsek, Mark Windfeld-Hansen, Scott Talbot, Thomas Blinka, and associates Steven Hwang, David Ambler, John Mills and Andrew Keith also provided support on this transaction.
Cooley represented AcelRx in its initial public offering in February 2011.
View the AcelRx press release here.
Related Posts:
- Cooley Advises Jazz Pharmaceuticals in $314.4 Million Offering
- Cooley Advises Jazz Pharmaceuticals in Acquisition of ADX-N05
- Isis Pharmaceuticals Completes Rule 144A Offering of $500 Million of Convertible Senior Notes
- Cooley Represents IDEV Technologies in Its Acquisition by Abbott Labs
- Cooley Advises Tableau Software on Its Initial Public Offering
